Cardlytics, Inc. (NASDAQ:CDLX) Receives $7.50 Average PT from Analysts

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been assigned a consensus recommendation of “Reduce” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.50.

CDLX has been the subject of several research reports. Needham & Company LLC lowered Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $7.00 to $5.00 in a report on Friday, August 16th. Craig Hallum lowered Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th.

Cardlytics Price Performance

Shares of Cardlytics stock opened at $3.43 on Monday. The business has a 50 day moving average of $6.23 and a 200 day moving average of $9.13. Cardlytics has a 52 week low of $2.89 and a 52 week high of $20.52. The company has a market cap of $167.33 million, a PE ratio of -0.78 and a beta of 1.65. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The firm had revenue of $69.64 million for the quarter, compared to analyst estimates of $75.39 million. During the same quarter in the previous year, the firm posted ($0.57) EPS. The company’s revenue for the quarter was down 9.2% compared to the same quarter last year. As a group, equities research analysts forecast that Cardlytics will post -1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Scott A. Hill bought 40,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the purchase, the director now owns 40,000 shares in the company, valued at $143,200. The acquisition was disclosed in a filing with the SEC, which is available through this link. In other Cardlytics news, Director Scott A. Hill bought 40,000 shares of Cardlytics stock in a transaction on Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, with a total value of $143,200.00. Following the completion of the acquisition, the director now owns 40,000 shares in the company, valued at $143,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Amit Gupta sold 22,699 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $8.66, for a total value of $196,573.34. Following the completion of the transaction, the chief operating officer now directly owns 150,569 shares in the company, valued at $1,303,927.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,613 shares of company stock valued at $362,840. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

Several large investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC increased its holdings in shares of Cardlytics by 193.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 78,546 shares of the company’s stock worth $723,000 after buying an additional 51,776 shares during the last quarter. Jump Financial LLC bought a new position in Cardlytics during the fourth quarter valued at $355,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Cardlytics in the 4th quarter worth about $719,000. Brown Advisory Inc. boosted its stake in shares of Cardlytics by 1.7% during the 4th quarter. Brown Advisory Inc. now owns 199,633 shares of the company’s stock worth $1,839,000 after purchasing an additional 3,257 shares during the period. Finally, Olympiad Research LP bought a new position in Cardlytics during the 4th quarter valued at about $247,000. Institutional investors own 68.10% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.